Search

Your search keyword '"Castellano, D. (Daniel)"' showing total 4 results
Start Over Author "Castellano, D. (Daniel)"
4 results on '"Castellano, D. (Daniel)"'

1. Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients

Author

Liu, X. (Xiaoyan), Swen, J.J. (Jesse), Boven, E. (Epie), Castellano, D. (Daniel), Gelderblom, H. (Hans), Mathijssen, A.H.J. (Ron), Rodríguez-Antona, C. (Cristina), García-Donas, J. (Jesus), Rini, B.I. (Brian I.), Guchelaar, H.J. (Henk Jan), Liu, X. (Xiaoyan), Swen, J.J. (Jesse), Boven, E. (Epie), Castellano, D. (Daniel), Gelderblom, H. (Hans), Mathijssen, A.H.J. (Ron), Rodríguez-Antona, C. (Cristina), García-Donas, J. (Jesus), Rini, B.I. (Brian I.), and Guchelaar, H.J. (Henk Jan)

Abstract

VEGFR1 rs9582036 and rs9554320 were previously reported the association with sunitinib progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). Hereafter, the association of both single nucleotide polymorphisms (SNPs) with PFS/OS was confirmed in two independent mRCC cohorts. The aim of the current study was to validate the associations of both SNPs with sunitinib outcome in three independent well-characterized cohorts (SUTOX, CCF and SOGUG) including 286 sunitinib-treated mRCC patients, as well as to perform a meta-analysis of current and published data combined. We found that rs9582036 and rs9554320 showed a significant association with sunitinib PFS in the CCF cohort (HR: 0.254, 95%CI: 0.092-0.703; P=0.008 and HR: 0.430, 95%CI: 0.200- 0.927

Published
2017
Full Text
View/download PDF

2. Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma

Author

Diekstra, F.P. (Frank), Liu, X. (Xiaoyan), Swen, J.J. (Jesse), Boven, E. (Epie), Castellano, D. (Daniel), Gelderblom, H. (Hans), Mathijssen, A.H.J. (Ron), Rodríguez-Antona, C. (Cristina), García-Donas, J. (Jesus), Rini, B.I. (Brian I.), Guchelaar, H.J. (Henk Jan), Diekstra, F.P. (Frank), Liu, X. (Xiaoyan), Swen, J.J. (Jesse), Boven, E. (Epie), Castellano, D. (Daniel), Gelderblom, H. (Hans), Mathijssen, A.H.J. (Ron), Rodríguez-Antona, C. (Cristina), García-Donas, J. (Jesus), Rini, B.I. (Brian I.), and Guchelaar, H.J. (Henk Jan)

Abstract

Purpose: Earlier, the association of single nucleotide polymorphisms (SNPs) with toxicity and efficacy of sunitinib has been explored in patients with metastatic renal cell

Published
2015
Full Text
View/download PDF

3. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma

Author

Prior, C. (Celia), Perez-Gracia, J.L. (José Luis), Garcia-Donas, J. (Jesús), Rodriguez-Antona, C. (Cristina), Guruceaga, E. (Elizabeth), Esteban, E. (Emilio), Suárez, C. (Cristina), Castellano, D. (Daniel), Gonzalez-del-Alba, A. (Aránzazu), Lozano, M.D. (María Dolores), Carles, J. (Joan), Climent, M.A. (Miguel Ángel), Arranz, J.A. (Jose Ángel), Gallardo, E. (Enrique), Puente, J. (Javier), Bellmunt, J. (Joaquim), Gurpide, A. (Alfonso), Lopez-Picazo, J.M. (José M.), Gonzalez-Hernandez, A. (Álvaro), Mellado, B. (Begoña), Martinez, E. (Esther), Moreno, F. (Fernando), Font, A. (Albert), Calvo, A. (Alfonso), Prior, C. (Celia), Perez-Gracia, J.L. (José Luis), Garcia-Donas, J. (Jesús), Rodriguez-Antona, C. (Cristina), Guruceaga, E. (Elizabeth), Esteban, E. (Emilio), Suárez, C. (Cristina), Castellano, D. (Daniel), Gonzalez-del-Alba, A. (Aránzazu), Lozano, M.D. (María Dolores), Carles, J. (Joan), Climent, M.A. (Miguel Ángel), Arranz, J.A. (Jose Ángel), Gallardo, E. (Enrique), Puente, J. (Javier), Bellmunt, J. (Joaquim), Gurpide, A. (Alfonso), Lopez-Picazo, J.M. (José M.), Gonzalez-Hernandez, A. (Álvaro), Mellado, B. (Begoña), Martinez, E. (Esther), Moreno, F. (Fernando), Font, A. (Albert), and Calvo, A. (Alfonso)

Abstract

We identified differentially expressed microRNAs in MRCC patients presenting marked sensitivity or resistance to sunitinib. MiR-942 was the best predictor of efficacy. We describe a novel paracrine mechanism through which high miR-942 levels in MRCC cells up-regulates MMP-9 and VEGF secretion to enhance endothelial migration and sunitinib resistance. Our results support further validation of these miRNA in clinical confirmatory studies.

Published
2014

4. Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population

Author

Castellano, D. (Daniel), Garcia-del-Muro, X. (X.), Perez-Gracia, J.L. (Jose Luis), Gonzalez-Larriba, J.L. (José Luis), Abrio, M.V. (M. V.), Ruiz, M.A. (M. A.), Pardo, A. (A.), Guzman, C. (C.), Diaz-Cerezo, S. (S.), and Grande-Pulido, E. (E.)

Subjects
Interferon-alfa, Patient-reported outcomes, Health-related quality of life, Sunitinib
Abstract

BACKGROUND: The purpose of this study is to evaluate the impact on the health-related quality of life (HRQoL) of sunitinib versus interferon-alpha (IFN-alpha) treatment in patients with metastatic renal cell carcinoma (mRCC). PATIENTS AND METHODS: In all, 304 mRCC patients (European cohort) were randomized 1 : 1 to receive sunitinib (50 mg/day for 4 weeks, followed by 2 weeks off) or IFN-alpha (9 million units s.c. injection three times/week). The following questionnaires were completed (days 1 and 28 per cycle): Functional Assessment of Cancer Therapy-General (FACT-G), the FACT-Kidney Symptom Index and the EuroQol Group's EQ-5D self-report questionnaire (EQ-5D). Results correspond to an ongoing trial with progression-free survival time as primary end point, and patients were still being followed up. Data were analyzed using repeated measures mixed effects models (MEMs) that allow the inclusion of initial differences and uncompleted repeated measures, with the assumption of data missing at random. Six-cycle results were included. RESULTS: Results consistently showed that patients in sunitinib group experienced statistically significantly milder kidney-related symptoms, better cancer-specific HRQoL and general health status (in social utility scores) during the study period as measured by these patient-reported outcome end points. No statistical differences between groups were found on the FACT-G physical well-being subscale or the EQ-5D VAS values. CONCLUSIONS: Results from MEM showed the sunitinib's benefit on HRQoL compared with IFN-alpha.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results